Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,390,000 shares, a decrease of 18.7% from the October 15th total of 4,170,000 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average daily trading volume, of 587,500 shares, the short-interest ratio is presently 5.8 days.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. SMH Capital Advisors Inc. purchased a new stake in shares of Standard BioTools during the fourth quarter worth $26,000. Jane Street Group LLC purchased a new stake in Standard BioTools in the 3rd quarter worth approximately $28,000. Marshall Wace LLP purchased a new stake in Standard BioTools in the 2nd quarter worth approximately $31,000. Walleye Capital LLC purchased a new stake in Standard BioTools in the 2nd quarter worth approximately $40,000. Finally, Acadian Asset Management LLC purchased a new stake in Standard BioTools in the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 57.61% of the company’s stock.
Standard BioTools Price Performance
Shares of NASDAQ LAB opened at $2.20 on Thursday. Standard BioTools has a one year low of $1.10 and a one year high of $3.16. The business’s fifty day moving average price is $2.31 and its 200-day moving average price is $2.30. The stock has a market capitalization of $174.67 million, a PE ratio of -2.29 and a beta of 1.48.
Standard BioTools Company Profile
Standard BioTools Inc, together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
- Five stocks we like better than Standard BioTools
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Do ETFs Pay Dividends? What You Need to Know
- 5 reasons TJX Companies will hit new highs in 2024
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.